Patients

Between January 2003 and October 2013, 449 children aged 1 to 18 years from the United Kingdom, Ireland, The Netherlands, Australia, and New Zealand diagnosed with relapsed BCP-ALL were enrolled on the ALLR3 trial (Figure 1).¹⁵ The study was approved by the relevant institutional ethics committee(s) and written informed consent was obtained for each patient from parents, legal guardians, or the patients themselves.¹⁵

CONSORT diagram depicting the patient cohorts used in this study with their key demographic and clinical features. “Age” refers to the mean age at relapse in years. *Material not available. E, early; F, female; HR, clinical high risk; L, late; M, male; VE, very early.